Excellent point by Drano “this is the method. Spread a
Excellent point by Drano “this is the method. Spread a lie, get jumpy shareholders to sell, and then, if the clinical trial results are good, well, they were able to get rid of some shareholders who won't buy in again.”
Excellent point by 4kids “I never focus on the PPS, that is how NR (non retail) and CEs (colluding entities) prey on retail investors”
Let me attempt to tie these 2 important points together. Look at yesterday’s trading where a supposed 1.58M shares were traded within a 2 cent range and the opening share price (SP) and closing share price was not within a penny or even a tenth of a penny but exactly the same one hundredth of a penny at .3036. Anyone paying attention to this statistical impossibility knew that this was simply an in-your-face market manipulation. Then today’s trading with similar B.S. and around noon there were 560k shares traded with minimal SP movement. In the last couple hours or so “volume” spiked to end at 3.39M shares and SP got slammed by over 4 cents. IMO if there has been any news that has leaked (not from IPIX itself) it is most likely positive news and possibly stellar news. Why would SP go down on upcoming good news? Because the criminals (Non Retail or NR) control IPIX SP and they are significantly upside-down on IPIX.
There are numerous milestones that I believe IPIX will achieve in the next few months and I do not want to minimize any of them including:
- B-IBD UC Phase 2 projected start date
- Rutgers RBL Brilacidin inflammation PR and/or Preprint
- Detailed DoD presentation that was to be given at military symposium
- EUA for B-CV19 from US and/or other country
- B-CV19 Phase 3 initiation
- Development of inhaler and/or depo delivery for B-CV19
- Key additions to the IPIX BOD
- Up List off of the corrupt OTX
…….but there are 2 very key milestones that will allow the above to take place and catapult IPIX to success which in turn will have a huge long term impact on IPIX SP. These 2 milestones are:
1) Successful B-CV19 trial results.
2) Funding (grants and/or partnerships).
Once these 2 key milestones take place there is absolutely no chance for any entity to stop IPIX’s success. The B-CV19 database lock has most likely taken place and the unbinding and analysis of the trial data is most likely underway by the CRO. Hopefully the CRO will provide the finalized data to IPIX by the end of the month and Leo will PR Top Line Results in early September. This is not a prediction of a timeline. The point is that no one knows the trial result at this point. There could however be agreements being drafted that are contingent on positive trial results which is what most IPIX investors believe will successfully happen.
I have a large group of friends and family that have followed me into investing in IPIX. I have told them all the very same point that 4kids makes which is that IPIX is a milestone investment and IPIX short term SP does not matter. The criminals (NR) will continue to collude to compress IPIX SP until they are no longer able to. IMO the milestones of trial success and funding will put a stake in their heart. (I hate to use this graphic of an analogy but I can’t think of a better one to describe the blood-suckers losing control). There will be a full court press by the criminals between now and Top Line results in the next month or so. The criminals will continue to collude by juggling shares amongst themselves and will most likely continue to dig themselves yet a deeper NSS hole. The criminals will use every FUD tactic in their playbook to try to scare investors into selling and to try to minimize the upside once trial results are indeed successfully announced. The criminals need IPIX investors to sell shares under the $5 range. The criminals need IPIX to become a trading stock vs the current environment of stubborn investors holding tight as they know what they own. Once IPIX share price is over $5 there will be institutional demand for the small biotech that has the first and only Covid-killer. Leading up to this we will see IPIX daily volumes in the 10M+ range and eventually in the 30M+ range once institutional demand kicks in. Every dollar increase in IPIX SP will cost the criminals $300M-$500M. At some point in the future when volume is high enough there will be a massive short squeeze. This cannot take place IMO until institutional investor demand kicks in and volume is in the 20M+ range on a consistent daily basis. In the Short term I am expecting IPIX SP to continue to be artificially compressed and very volatile. The criminals will do their best to condition retail investors to trade and sell their IPIX positions. IMO the pendulum will start to swing after successful trial results and funding are announced. IMO the most significant gains in IPIX SP will take place the end of this year and throughout 2022.
18
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
When Money Talks Fast: Market Funds Smash Records Picture this: money market funds have surged to an eye-watering $7.98 trillion. That's a lot of zeros, folks. And it's not just the usual humdrum growth; we're talking a hefty $44.75 billion increase in just one week, thanks to a cocktail of government funds and prime fund muscle, as the Investment Company Institute (ICI)...
Continue Reading
A Bold Play in the Global Arena There's something big brewing on the horizon, as Haier aligns with the UEFA Champions League. From 2027 to 2031, this move isn't just about slapping a logo on a jersey. Nah, it's more than that. Haier's stepping up its game, aiming to become a real player in weaving technology and sports into the daily lives of millions. "We aim to bring...
Continue Reading
Curaleaf's Bold Moves in Florida's Ganja Gold Rush Fresh out of the gate, Curaleaf is saddling up for a wild ride into Florida's cannabis frontier. They've just thrown open the doors of their latest dispensary in Riverview, cranking their statewide count up to 77. Now, isn’t that something? If you're tracking these folks, you know that bringing their nationwide total to...
Continue Reading
Transamerica's Next Phase: Leadership Moves in Retirement Transamerica just pulled a move that’s both bold and calculated. They’ve beefed up their retirement distribution squad with Danny Kling and Kevin Murphy stepping into the spotlight. These guys are bringing heaps of experience and a fresh jolt of energy to keep the momentum going. No doubt this is Transamerica...
Continue Reading
Ticking Clock for Wix Investors' Legal Moves The buzz in the stock market is louder than a bull on Wall Street, especially if you're tangled up with Wix.com Ltd. (NASDAQ: WIX). We've got Faruqi & Faruqi, LLP laying down serious advice: move fast or maybe lose your spot in line. The deadline to noodle over your position as a lead plaintiff in their federal securities class...
Continue Reading
A Glimpse Into The Future: Asia-Pacific's Tech Landscape There's a unique transformation bubbling across the Asia-Pacific scene, with young minds pushing the envelope on technology and innovation. Take Nathapol's team from Thailand, for example. They're merging bionic tech with drones for disaster relief—bold, ambitious, and nearly clinching glory at the Lancang-Mekong...
Continue Reading
Pioneering English Confidence for the Global Workplace Stepping into a meeting with international partners requires more than just textbook knowledge of English. It's about confidently expressing ideas, adapting on the fly, and engaging with global colleagues. Enter EF English Live, a leader in transforming workplace communication through targeted English learning. Expert...
Continue Reading
UGREEN Unveils a Cool Revolution in Charging Out in Foxborough, UGREEN is shaking things up at its Smart Living Launch Event. The big reveal? The MagFlow Series, their flagship wireless charging lineup, which promises faster and cooler charging than ever before. UGREEN's taking wireless charging to new heights, and that's got my attention. What Makes MagFlow Stand Out...
Continue Reading
The Future of Financial Bridging Now here's a scenario that might perk your ears up if you've ever toyed with digital assets: APX Lending is stepping up its game, bringing a regulated five-year revolving line of credit backed by Bitcoin and Ethereum to the world stage. It's like blending your grandma's tried-and-true savings approach with the whiz-bang allure of crypto. A...
Continue Reading
A Surprise Win in the Beauty World Who doesn't love an underdog story, right? Beverly Hills MD has slid into the limelight with their Dermal Repair Complex snagging the award for 'Beauty Product of the Year.' Talk about sending shockwaves through the beauty industry! Now, these guys might not be a household name yet, but you better believe they've got everyone's attention...
Continue Reading
Top 5 Most Recently Viewed Articles
NTS Innovations Invites Investment to Transform Power Generation NTS Innovations, a cutting-edge nanotechnology company championing semiconductor-based energy harvesting, is excited to announce its funding campaign on StartEngine. This innovative platform offers an exceptional opportunity for both seasoned and new investors to get involved in a venture that is set to...
Continue Reading
RCI Banque Explores Green Bond Allocation RCI Banque, a key player in innovative financing solutions, has made headlines with the recent release of their statutory auditors report on Green Bond allocation. This report sheds light on how the funds raised through Green Bonds are being utilized to promote environmentally sustainable projects. Importance of Green Bonds Green...
Continue Reading
Dancecoin Launches Initial Exchange Offering on Coinstore In a groundbreaking move for the dance community, Coinstore has embarked on the Initial Exchange Offering (IEO) of Dancecoin’s native token, DANCE ($DANCE). This momentous occasion is set to be celebrated with the listing of the token as a DANCE/USDT pair, marking its trading debut not too far off. A...
Continue Reading
Kinross Gold Corporation Announces an Increase in Dividend Kinross Gold Corporation (TSX: K, NYSE: KGC) has recently made headlines with exciting news for its investors. The company's Board of Directors has approved a remarkable 17% increase in its annual dividend, which now stands at $0.14 per share. This move is a testament to Kinross's commitment to providing...
Continue Reading
JPMorgan's Perspective on H&M During Brand Transformation Recently, JPMorgan reaffirmed its Underweight rating on Hennes & Mauritz AB (HMB:SS) stock. They provided insights into the hurdles H&M is facing with its brand refresh efforts. Currently, JPMorgan has set a price target of SEK130.00, as they keep a close eye on how the market reacts to H&M's latest fashion...
Continue Reading